|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome 显示文摘 | Carey LA Metzger R Dees EC | 2005 | J Natl Cancer Inst2005，97，15： | 1 |
| 2 | The proteasome as a target for cancer therapy显示文摘 | Vorhees PM Dees EC O Neil B | 2003 | Clin Cancer Res2003，9，： | 1 |
| 3 | The triple negative paradox: primary tumor chemoseasitivity of breast cancer subtypes 显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，6： | 1 |
| 4 | The triple-negative paradox primary tumor chemosensitivity of breast cancer subtypes显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 5 | The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes显示文摘 | Carey LA Dees EC Sawyer L et a1 | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 6 | The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 7 | Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer 显示文摘 | Dees EC Mckinnon KP Kuhns JJ | 2004 | Cancer Immunol Immunother2004，53，9： | 1 |
| 8 | The triple negative para-dox:primary tumor chemosensitivity of breast cancer subtypes显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 9 | Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016) , a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas 显示文摘 | Burris HA III Hurwitz HI Dees EC | 2005 | J Clin Oncol2005，23，： | 1 |
| 10 | Phase II trial of capecitabine and veekly paclitaxel as first-line therapy for metastatic breast cancer显示文摘 | llum JL Dees EC Chacko A | 2006 | J 21in Oneol2006，24，27： | 1 |
| 11 | The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes显示文摘 | CAREY LA DEES EC SAWYER L | 2007 | Clin Cancer Res2007，3，8： | 1 |
| 12 | The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 13 | The triple negative paradox: primary tumor chernosensitivity of breast cancer subtypes 显示文摘 | Carey AL Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 14 | The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes 显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 15 | The triple negative paradox: primary tumor chemosensitivity of breast cancer subtype显示文摘 | Carey LA Dees EC Sawyer L | 2007 | Clin Cancer Res2007，13，8： | 1 |
| 16 | Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinb(GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas显示文摘 | Burris HA 3rd Hurwiz HI Dees EC | 2005 | J Clin Oncol2005，23，： | 1 |
| 17 | The proteasome as a target for cancer therapy显示文摘 | Voorhees PM Dees EC O'NeilB | 2003 | Clin Cancer Res2003，9，： | 1 |
| 18 | The Proteasome as a target for Cancer Therapy 显示文摘 | Voorhees PM Dees EC O' Neff B Orlowski RZ | 2003 | Clin Cancer Res2003，9，17： | 1 |
| 19 | Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib(GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas显示文摘 | Burris HA 3rd Hurwitz HI Dees EC | 2005 | J Clin Oncol2005，23，23： | 1 |
| 20 | Targeting the ubiquitin-proteasome pathway in breast cancer therapy 显示文摘 | Dees EC Orlowski RZ | 2006 | Future Oncot2006，2，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员